Search Clinical Trials
Before medications are approved by the U.S. Food and Drug Administration (FDA) or before certain therapy methods are widely accepted as effective, they are tested on people who volunteer to participate in a clinical trial.
Organizations across the country are looking for people like you to take part in their research studies. The list of studies below have been selected from ClinicalTrials.gov based on their inclusion of one or more of the following terms: anxiety disorders, depression, OCD, PTSD, and bipolar disorder.
The Anxiety and Depression Association of America (ADAA) is supportive of research that is conducted through clinical trials. Participating in research can potentially help change the mental health outcomes for you and others who suffer anxiety, depression, and related disorders. You may learn about new interventions/treatments that are being considered.
Read this ADAA blog about things to know and questions to ask before committing to a clinical trial.
This website page is brought to you in partnership with ResearchMatch.
Sponsor Condition of Interest |
---|
Restorative Early Sleep Treatment After the Emergency Department
Henry Ford Health System
Insomnia
Nightmares Associated With Trauma and Stress
Nightmares
PTSD - Post Traumatic Stress Disorder
The goal of this randomized controlled trial is to pilot the virtual delivery of
cognitive behavioral therapy for insomnia (CBT-I) and nightmares (CBT-I&N) via telehealth
as an early intervention for treating posttraumatic sleep disturbance in acute trauma
patients exposed to interpersonal violence1 expand
The goal of this randomized controlled trial is to pilot the virtual delivery of cognitive behavioral therapy for insomnia (CBT-I) and nightmares (CBT-I&N) via telehealth as an early intervention for treating posttraumatic sleep disturbance in acute trauma patients exposed to interpersonal violence. The main aims are to: 1. Test the acceptability, feasibility, and satisfaction of sleep-focused CBT delivered early after trauma 2. Evaluate the impact of sleep-focused CBT delivered early after trauma on sleep disturbance 3. Evaluate the impact of sleep-focused CBT delivered early after trauma on PTSD symptoms The investigators will compare CBT-I and CBT-I&N to sleep education control. Participants will meet with a provider for 6 weekly sessions via telehealth and complete surveys on the participants' symptoms. Type: Interventional Start Date: Mar 2025 |
Treatment for PTSD and Tinnitus
The University of Texas Health Science Center at San Antonio
PTSD - Post Traumatic Stress Disorder
Posttraumatic Stress Disorder (PTSD)
Tinnitus
In this study, researchers are examining the best sequence of interventions for
posttraumatic stress disorder (PTSD) and tinnitus. Participants will either receive
psychotherapy for PTSD first (Cognitive Processing Therapy; CPT), followed by treatment
for tinnitus (Cognitive Behavioral Therapy for1 expand
In this study, researchers are examining the best sequence of interventions for posttraumatic stress disorder (PTSD) and tinnitus. Participants will either receive psychotherapy for PTSD first (Cognitive Processing Therapy; CPT), followed by treatment for tinnitus (Cognitive Behavioral Therapy for Tinnitus; CBT-t); or vice-versa. We also aim to identify changes in brain functioning after receiving therapy. Type: Interventional Start Date: Aug 2025 |
Hypnosis-Based Machine Learning Biomarker Study
Icahn School of Medicine at Mount Sinai
Disorder; Trance
Anxiety
This study seeks to contribute to the growing body of literature on hypnosis by providing
robust, data-driven insights into the physiological mechanisms underlying trance states.
The integration of electroencephalogram (EEG) and other wearable-derived physiological
data will offer a comprehensive a1 expand
This study seeks to contribute to the growing body of literature on hypnosis by providing robust, data-driven insights into the physiological mechanisms underlying trance states. The integration of electroencephalogram (EEG) and other wearable-derived physiological data will offer a comprehensive assessment of the changes that occur during a standardized hypnosis protocol: the Harvard Group Scale of Hypnotic Susceptibility (HGSHS:A). The results of this study are intended to facilitate derivation and validation of an Artificial Intelligence/Machine Learning (AI/ML)-based monitor that quantifies a patient's instantaneous emotional/arousal state along the spectrum that spans anxiety through states of calmness and trance. Future investigations will explore the ability of using such an interactive virtual system as a component of a closed-loop adaptive device to create optimal states of non-pharmacological sedation using personalized audiovisual content to allay anxiety and discomfort during medical procedures, such as percutaneous biopsies. Type: Interventional Start Date: Aug 2025 |
Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Dep1
University of North Carolina, Chapel Hill
Antenatal Depression
Major Depressive Disorder
Major Depressive Disorder in Pregnancy
Healthy Controls
The purpose of this study is to develop the safety, feasibility, and tolerability of a
personalized transcranial alternating current stimulation (tACS) approach in antenatal
depression. expand
The purpose of this study is to develop the safety, feasibility, and tolerability of a personalized transcranial alternating current stimulation (tACS) approach in antenatal depression. Type: Interventional Start Date: Aug 2025 |
Autonomous Digital CBT Intervention for Opioid Use Disorder in Individuals With Co-Occurring Intern1
University of Minnesota
Opioid Use Disorder
Anxiety
Depression
The primary objective of this protocol is to implement the UG3 phase (Phase 1) of a
National Institute on Drug Abuse (NIDA) UG3/UH3 grant (RFA-DA-23-049). This phase is
dedicated to the pilot testing of NEAT-O, a digital Cognitive Behavioral Therapy (CBT)
program tailored for individuals with opioi1 expand
The primary objective of this protocol is to implement the UG3 phase (Phase 1) of a National Institute on Drug Abuse (NIDA) UG3/UH3 grant (RFA-DA-23-049). This phase is dedicated to the pilot testing of NEAT-O, a digital Cognitive Behavioral Therapy (CBT) program tailored for individuals with opioid use disorder (OUD) and concurrent anxiety or mood disorders - collectively referred to as internalizing disorders (INTDs). NEAT-O is based on an empirically supported CBT framework, specifically modified to address the complexities of comorbidity in substance use disorders (SUDs). This pilot study will evaluate the usability and acceptability of NEAT-O in 15 participants with OUD, with the goal of refining the program's content and delivery methods. The results of the pilot study will inform a comprehensive RCT in the UH3 Phase (Phase 2) (N=300). Progression to the UH3 phase, with its funding, depends on meeting milestones in Phase 1 including demonstrating protocol adherence and the program's acceptability and usability. Type: Interventional Start Date: Aug 2025 |
PRISM for Depression and Anxiety in Young Adults With Cancer
Dana-Farber Cancer Institute
Cancer Diagnosis
Non-Metastatic Neoplasm
Anxiety
Anxiety Disorders
Depression
This research study is being done to test the feasibility of an existing supportive
program (PRISM) to address psychological symptoms (i.e., depressive and anxiety symptoms)
that young adult participants diagnosed with cancer or desmoid tumor may experience.
The name of the intervention used in th1 expand
This research study is being done to test the feasibility of an existing supportive program (PRISM) to address psychological symptoms (i.e., depressive and anxiety symptoms) that young adult participants diagnosed with cancer or desmoid tumor may experience. The name of the intervention used in this research study is: -Promoting Resilience in Stress Management (PRISM) Program Type: Interventional Start Date: Sep 2024 |
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
University of Wisconsin, Madison
Anxiety
Depression
Depression, Anxiety
Anxiety Disorders
The goal of this research study is to adapt an ACT-self-help workbook to the prison
setting and determine the feasibility acceptability, and effectiveness of this workbook.
Participants can expect to be in the study for 13 weeks. expand
The goal of this research study is to adapt an ACT-self-help workbook to the prison setting and determine the feasibility acceptability, and effectiveness of this workbook. Participants can expect to be in the study for 13 weeks. Type: Interventional Start Date: Dec 2024 |
Neuro-affective Response to Light in Depressed Adolescents and Young Adults
University of Pittsburgh
Depression in Adolescence
Depression in Adults
The goal of this neuroimaging pilot study is to understand developmental differences in
the impact of therapeutic wavelength light (blue light) versus a non-therapeutic
wavelength (red light) on emotional brain function in depression. The main questions this
study aims to answer are:
- Does acu1 expand
The goal of this neuroimaging pilot study is to understand developmental differences in the impact of therapeutic wavelength light (blue light) versus a non-therapeutic wavelength (red light) on emotional brain function in depression. The main questions this study aims to answer are: - Does acute exposure to blue light (vs red light) stabilize emotional brain function in depressed individuals? - Are stabilizing effects of blue light (vs red light) stronger for blue light in adolescents than young adults? Participants will complete: - A magnetic resonance imaging brain scan, in which we will examine the effect of blue versus red light on emotional brain function at rest and in response to rewards and losses. - A pupillometry test of sensitivity to blue vs red light - Clinical interviews and surveys - Screening measures for drug and alcohol use, MRI safety, and current pregnancy [if relevant] - Home sleep tracking with sleep diary and actigraphy for one week Type: Interventional Start Date: Jun 2023 |
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treat1
AbbVie
Depression
Bipolar I Disorder
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult
population and 1.8% of the pediatric population in the United States. The treatment of
the depressive episodes of bipolar disorder in the pediatric population has not been as
widely studied as the treatment of dep1 expand
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associated with bipolar I disorder, the purpose of this study is to evaluate the change in disease state and safety of cariprazine in the treatment of depressive episodes associated with bipolar I disorder in the pediatric population. Cariprazine is an approved drug for the treatment of depressive episodes in adult participants with bipolar I disorder. Study doctors put participants in 1 of 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 380 Participants ages 10-17 years with bipolar I disorder will be enrolled in approximately 60 sites worldwide. Participants receiving the study drug will receive Dose A or B of Cariprazine based on age and weight. At Week 3, participants with insufficient response will have their dose increased to Dose B or Dose C, while participants with sufficient response will continue receiving the Dose A or B for the remainder of the treatment period. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires. Type: Interventional Start Date: Apr 2021 |
Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes
M.D. Anderson Cancer Center
Anxiety Disorder
Depression
Genetic Disorder
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
This study evaluates the association between testosterone levels and risk of dementia and
adverse mental health outcomes (e.g. depression and anxiety). It is not known whether low
testosterone levels may be associated with an increased risk of dementia. Learning about
the association between testos1 expand
This study evaluates the association between testosterone levels and risk of dementia and adverse mental health outcomes (e.g. depression and anxiety). It is not known whether low testosterone levels may be associated with an increased risk of dementia. Learning about the association between testosterone levels and risk of dementia may help determine the long-term effects of androgen deprivation therapy and may help improve quality of life. Type: Observational Start Date: Feb 2020 |
Defining Neurobiological Links Between Substance Use and Mental Illness
National Institute on Drug Abuse (NIDA)
Major Depressive Disorder
Substance Use Disorder
Normal Physiology
Background:
Nicotine dependence leads to about 480,000 deaths every year in the United States. People
with major depressive disorder (MDD) are twice as likely to use nicotine compared to the
general population. They have greater withdrawal symptoms and are more likely to relapse
after quitting com1 expand
Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population. They have greater withdrawal symptoms and are more likely to relapse after quitting compared with smokers without MDD. More research is needed on how nicotine affects brain function in those with MDD. Objective: To understand how nicotine affects symptoms of depression and related brain function. Eligibility: People aged 18 to 60 years, at the time of consent, with and without MDD who do not smoke cigarettes or use other nicotine products. Design: Participants will have 2 or 3 study visits over 1 year. Participants will have 2 MRI scans no less than 4 days apart. Each scan visit will last 5 to 7 hours. At each scan, they will have urine and breath tests to screen for recent use of alcohol, nicotine, and illegal drugs. Before each scan, they will take 1 of 2 medications: nicotine or placebo. Participants will receive each medication once. They will not know which medication they are receiving at each scan. For each MRI scan, they will lie on a table that slides into a cylinder. Sometimes they will be asked to lie still. Sometimes they will complete tasks on a computer. Tasks may include identifying colors or playing games to win money. Each scan will take about 2 hours. Participants will answer questions about their thoughts, feelings, and behaviors before and after each scan. They will have a blood test after each scan. Type: Interventional Start Date: Feb 2023 |
PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.
Stony Brook University
Major Depressive Disorder (MDD)
In the brain, certain nerve cells communicate using a chemical called acetylcholine.
Acetylcholine is thought to be important for several functions including mood, memory and
wakefulness. The purpose of this study is to explore the role of these nerve cells in
depression. Also, we would like to und1 expand
In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment. Type: Interventional Start Date: Oct 2024 |
Brief Exposure and Exercise for PTSD.
Troy Hubert
PTSD - Post Traumatic Stress Disorder
The goal of this clinical trial is to learn if 8 sessions of brief exposure and exercise
therapy works to treat Post Traumatic Stress Disorder (PTSD) in adults. This study will
also learn if participants think brief exposure and exercise therapy is a good and doable
treatment. and The main question1 expand
The goal of this clinical trial is to learn if 8 sessions of brief exposure and exercise therapy works to treat Post Traumatic Stress Disorder (PTSD) in adults. This study will also learn if participants think brief exposure and exercise therapy is a good and doable treatment. and The main questions it aims to answer are: - Do participants find brief exposure and exercise an acceptable and feasible means of treatment for PTSD? - Does brief exposure and exercise decreases of the severity of PTSD symptoms? Participants will: - Complete weekly questionnaires for 10-14 weeks. - Attend 8 twice weekly exposure therapy and exercise sessions for 4 weeks. Type: Interventional Start Date: Jun 2025 |
Developing Evidence-Based Cognitive Approaches to Improve Adjustment to Vision Loss
The Chicago Lighthouse
Depression, Anxiety
Visual Impairment
Adjustment
Adjustment Disorder With Anxious Mood
Adjustment Disorder With Depressed Mood
The goal of this study is to develop and pilot test a therapeutic strategy combining
cognitive behavioral therapy (CBT) with mindfulness practices tailored for individuals
adjusting to vision loss. The study will begin with focus groups to inform the design of
the intervention. Participants will co1 expand
The goal of this study is to develop and pilot test a therapeutic strategy combining cognitive behavioral therapy (CBT) with mindfulness practices tailored for individuals adjusting to vision loss. The study will begin with focus groups to inform the design of the intervention. Participants will complete brief surveys on their background and experiences with vision loss prior to attending a focus group, and some may be invited to a second session to provide additional feedback before preliminary testing begins. In the pilot phase, participants will attend weekly group therapy sessions using the developed intervention and complete assessments before and after the program, including questions about vision status, demographics, and experiences with vision loss. Type: Interventional Start Date: Jul 2025 |
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depre1
Seaport Therapeutics
Major Depressive Disorder (MDD)
Major Depressive Disorder With Anxious Distress
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study
to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with
major depressive disorder (MDD), with or without anxious distress. expand
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress. Type: Interventional Start Date: Jul 2025 |
Video-feedback Intervention to Promote Racial-Ethnic Socialization Competency (VIP-RACE)
Penn State University
Depressive Symptoms
Anxiety Symptoms
Conduct Problems
The aim of this study is to evaluate a novel cultural strengths parenting program - the
Video-feedback Intervention to Promote Racial-Ethnic Socialization CompEtency (VIP-RACE)
- which seeks to support Latine parents' motivation to engage in racial-ethnic
socialization (RES) and strengthen their RE1 expand
The aim of this study is to evaluate a novel cultural strengths parenting program - the Video-feedback Intervention to Promote Racial-Ethnic Socialization CompEtency (VIP-RACE) - which seeks to support Latine parents' motivation to engage in racial-ethnic socialization (RES) and strengthen their RES competency (improved skills and confidence, decreased stress). In the preliminary phases of this project, we iteratively refined the VIP-RACE program in partnership with advisory boards of youth, parents, and providers. The refined intervention will now be tested with five parents of 10-14-year-old Latine youth to identify gaps in the curriculum and obstacles to implementation that can be addressed prior to a larger pilot. The investigators will then conduct a proof-of-concept single-arm trial with Latine families to assess the feasibility, acceptability, and preliminary efficacy of VIP-RACE. The investigators hypothesize that VIP-RACE will be shown to be feasible and acceptable to families. The investigators also predict that bolstering parents' RES motivation and competency will result in increased frequency and quality of these conversations between parents and youth which, in turn, are expected to strengthen youth racial-ethnic identity and coping and have cascading effects on mental and behavioral health. Type: Interventional Start Date: May 2025 |
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
Rapport Therapeutics Inc.
Bipolar 1 Disorder
This is a clinical research study for an investigational drug called RAP-219 in
participants with bipolar I disorder. This study is being conducted to determine if
RAP-219 is safe and effective in participants experiencing mania associated with bipolar
I disorder. expand
This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder. Type: Interventional Start Date: Jul 2025 |
Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Diso1
University of Pittsburgh
Schizophenia Disorder
Schizoaffective Disorder
Bipolar Disorder
Psychiatric Disorders
The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with
psychoses or serious mental illness, when these medications are no longer needed. expand
The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed. Type: Interventional Start Date: Jul 2025 |
Music Use in Parturients Admitted to Labor & Delivery
Tufts Medical Center
Anxiety
Pain
Patient Satisfaction
The goal of this clinical trial is to learn if music use affects anxiety or pain levels
in parturients admitted to labor and delivery. It will also learn about the effect of
music use on patient satisfaction. The main questions it aims to answer are:
Does music use affect anxiety levels in parturi1 expand
The goal of this clinical trial is to learn if music use affects anxiety or pain levels in parturients admitted to labor and delivery. It will also learn about the effect of music use on patient satisfaction. The main questions it aims to answer are: Does music use affect anxiety levels in parturients admitted to labor and delivery? Does music use affect pain levels in parturients admitted to labor and delivery? Does music use affect patient satisfaction in parturients admitted to labor and delivery? Researchers will compare music to a control (no music) to see if music affects anxiety levels in parturients admitted to labor and delivery. Participants will: Listen to music or listen to no music for a 10 minute duration in the labor and delivery unit. Answer questions about anxiety and pain levels at a few different timepoints. Have information collected from medical charts (vital signs and cervical dilation). Rate their satisfaction with care. Type: Interventional Start Date: May 2025 |
Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depres1
University of Pittsburgh
Sleep Disturbance
Sleep
Depression
Suicide
The goal of this clinical trial is to adapt a sleep intervention for individuals
representative of all demographic groups, including those who are at the highest risk for
suicidal behavior. Sleep difficulties are a promising target for youth with suicidal
thoughts and behavior to focus on as a prev1 expand
The goal of this clinical trial is to adapt a sleep intervention for individuals representative of all demographic groups, including those who are at the highest risk for suicidal behavior. Sleep difficulties are a promising target for youth with suicidal thoughts and behavior to focus on as a prevention measure. We aim to increase intervention acceptability and impact by adapting it for the adolescent populations at highest risk for suicidal thoughts and behavior. The research project will compare Transdiagnostic Sleep and Circadian Intervention (TranS-C), an evidence based, modularized intervention that targets a range of sleep difficulties to a treatment as usual or control condition including providing weekly sleep feedback reports from data entered into a daily sleep diary and from wearing a sleep sensing, actigraphy watch. Participants in both conditions (TranS-C vs. Sleep Feedback) will wear an actigraphy sleep watch that monitors sleep, and complete daily sleep diaries via smartphone or email. Participants in the TranS-C condition will also wear bright light (BL) and blue blocking glasses each day as well as attend weekly or biweekly sessions with a Sleep Therapist. The sleep therapist will review sleep feedback during sessions. Type: Interventional Start Date: May 2025 |
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Di1
Bristol-Myers Squibb
Bipolar Disorder Type I With Mania
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for
the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I)
The primary objective of the study is to evaluate the long-term safety and tolerability
of KarXT in the treatment of participan1 expand
This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I. Type: Interventional Start Date: Jul 2025 |
Well-being Training for Adolescent Depressive Symptoms (TeenWell Study)
University of Wisconsin, Madison
Depression
This study is being done to see if the Healthy Minds Program app helps adolescents with
elevated depressive symptoms. Up to 200 participants will be on study for 20 weeks. expand
This study is being done to see if the Healthy Minds Program app helps adolescents with elevated depressive symptoms. Up to 200 participants will be on study for 20 weeks. Type: Interventional Start Date: Dec 2024 |
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major1
Janssen Research & Development, LLC
Depressive Disorder, Major
The purpose of this study is to know how well seltorexant works, and also to evaluate
safety and maintenance effect of seltorexant compared with placebo as an adjunctive
therapy to an antidepressant in improving depressive symptoms in participants with major
depressive disorder with insomnia sympto1 expand
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI). Type: Interventional Start Date: Jul 2024 |
Imaging Depression in Parkinson's Disease
Yale University
Parkinson's Disease
Major Depressive Disorder
The goal of this observational study is to identify targetable neural substrates of
depression in Parkinson's Disease for the first time in people with Parkinson's between
the ages of 40 and 80, who are experiencing symptoms of depression. expand
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression. Type: Interventional Start Date: Dec 2025 |
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
University of California, San Diego
Anxiety Disorders
Depression
Post Traumatic Stress Disorder
The proposed project aims to test the cognitive and neural effects of a cognitive
training in a sample of individuals seeking treatment for anxiety, depression, or
traumatic stress symptoms. Participants will be randomly assigned to one of two groups.
Group 1 will receive a computer-based program t1 expand
The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups. Group 1 will receive a computer-based program that is designed as a cognitive training intervention and Group 2 will receive a similar computer-based exercise that researchers think will be less effective in training thinking skills (also known as a control or sham condition). Participants will be compared on cognitive performance and brain response during cognitive tasks from baseline to post-treatment. Type: Interventional Start Date: Oct 2024 |
- Previous
- Next